Asymmetrical dimethylarginine (ADMA) and coronary endothelial function in patients with coronary artery disease and mild hypercholesterolemia

Atherosclerosis

Volumn 191, Issue 1, 2007, Pages 211-219

  Maas, Renke ^a   Quitzau, Kurt ^b   Schwedhelm, Edzard ^a   Spieker, Lukas ^b   Rafflenbeul, Wolf ^c   Steenpaß, Anna ^a   Lüscher, Thomas F ^b   Böger, Rainer H ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

ADMA; Coronary artery; Endothelial dysfunction; Hypercholesterolemia; Nitric oxide synthase inhbitor

Indexed keywords

ACETYLCHOLINE; ADENOSINE; ARGININE; CERIVASTATIN; GLYCERYL TRINITRATE; N(G),N(G) DIMETHYLARGININE; NIFEDIPINE; NITRIC OXIDE SYNTHASE INHIBITOR; PLACEBO;

ADULT; AGED; ARTICLE; BLOOD LEVEL; BLOOD VESSEL REACTIVITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VASCULAR ENDOTHELIUM; VASODILATATION;

ACETYLCHOLINE; ADENOSINE; AGED; ARGININE; CORONARY ARTERIOSCLEROSIS; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; MALE; MIDDLE AGED; NITROGLYCERIN; VASOCONSTRICTION; VASOCONSTRICTOR AGENTS; VASODILATION; VASODILATOR AGENTS;

EID: 33846881147     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2006.03.024     Document Type: Article

References (49)

1. Lu T.M., Ding Y.A., Lin S.J., Lee W.S., and Tai H.C. Plasma levels of asymmetrical dimethylarginine and adverse cardiovascular events after percutaneous coronary intervention. Eur Heart J 24 21 (2003) 1912-1919
2. Valkonen V.P., Paiva H., Salonen J.T., et al. Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet 358 9299 (2001) 2127-2128
3. Nijveldt R.J., Teerlink T., Van Der Hoven B., et al. Asymmetrical dimethylarginine (ADMA) in critically ill patients: high plasma ADMA concentration is an independent risk factor of ICU mortality. Clin Nutr 22 1 (2003) 23-33
4. Schnabel R., Blankenberg S., Lubos E., et al. Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease: results from the AtheroGene Study. Circ Res 97 5 (2005) e53-e59
5. Vallance P., Leone A., Calver A., Collier J., and Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 339 8793 (1992) 572-575
6. Segarra G., Medina P., Vila J.M., et al. Inhibition of nitric oxide activity by arginine analogs in human renal arteries. Am J Hypertens 14 11 Pt 1 (2001) 1142-1148
7. Faraci F.M., Brian Jr. J.E., and Heistad D.D. Response of cerebral blood vessels to an endogenous inhibitor of nitric oxide synthase. Am J Physiol 269 5 Pt 2 (1995) H1522-H1527
8. Calver A., Collier J., Leone A., Moncada S., and Vallance P. Effect of local intra-arterial asymmetric dimethylarginine (ADMA) on the forearm arteriolar bed of healthy volunteers. J Hum Hypertens 7 2 (1993) 193-194
9. Böger R.H., Bode-Böger S.M., Szuba A., et al. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation 98 18 (1998) 1842-1847
10. Stühlinger M.C., Oka R.K., Graf E.E., et al. Endothelial dysfunction induced by hyperhomocyst(e)inemia: role of asymmetric dimethylarginine. Circulation 108 8 (2003) 933-938
11. Sydow K., Schwedhelm E., Arakawa N., et al. ADMA and oxidative stress are responsible for endothelial dysfunction in hyperhomocyst(e)inemia: effects of l-arginine and B vitamins. Cardiovasc Res 57 1 (2003) 244-252
12. Perticone F., Sciacqua A., Maio R., et al. Asymmetric dimethylarginine, l-arginine, and endothelial dysfunction in essential hypertension. J Am Coll Cardiol 46 3 (2005) 518-523
13. Kielstein J.T., Bode-Böger S.M., Frölich J.C., Ritz E., Haller H., and Fliser D. Asymmetric dimethylarginine, blood pressure, and renal perfusion in elderly subjects. Circulation 107 14 (2003) 1891-1895
14. Achan V., Broadhead M., Malaki M., Whitley G., Leiper J., MacAllister R., and Vallance P. Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase. Arterioscler Thromb Vasc Biol 23 8 (2003) 1455-1459
15. Kielstein J.T., Impraim B., Simmel S., et al. Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humans. Circulation 109 2 (2004) 172-177
16. Goonasekera C.D., Shah V., Rees D.D., and Dillon M.J. Vascular endothelial cell activation associated with increased plasma asymmetric dimethylarginine in children and young adults with hypertension: a basis for atheroma?. Blood Press 9 1 (2000) 16-21
17. Piatti P., Fragasso G., Monti L.D., et al. Acute intravenous l-arginine infusion decreases endothelin-1 levels and improves endothelial function in patients with angina pectoris and normal coronary arteriograms: correlation with asymmetric dimethylarginine levels. Circulation 107 3 (2003) 429-436
18. Hori T., Matsubara T., Ishibashi T., et al. Significance of asymmetric dimethylarginine (ADMA) concentrations during coronary circulation in patients with vasospastic angina. Circ J 67 4 (2003) 305-311
19. ENCORE Investigators. Effect of nifedipine and cerivastatin on coronary endothelial function in patients with coronary artery disease: the ENCORE I Study (Evaluation of Nifedipine and Cerivastatin On Recovery of coronary Endothelial function). Circulation 107 3 (2003) 422-428
20. Maas R., Böger R.H., Schwedhelm E., et al. Plasma concentrations of asymmetric dimethylarginine (ADMA) in Colombian women with pre-eclampsia. JAMA 291 7 (2004) 823-824
21. Schwedhelm E. Quantification of ADMA: analytical approaches. Vasc Med 10 Suppl 1 (2005) S89-S95
22. Bode-Böger S.M., Muke J., Surdacki A., Brabant G., Böger R.H., and Frölich J.C. Oral l-arginine improves endothelial function in healthy individuals older than 70 years. Vasc Med 8 2 (2003) 77-81
23. Walker H.A., McGing E., Fisher I., et al. Endothelium-dependent vasodilation is independent of the plasma l-arginine/ADMA ratio in men with stable angina: lack of effect of oral l-arginine on endothelial function, oxidative stress and exercise performance. J Am Coll Cardiol 38 2 (2001) 499-505
24. Mittermayer F., Schaller G., Pleiner J., et al. Asymmetrical dimethylarginine plasma concentrations are related to basal nitric oxide release but not endothelium-dependent vasodilation of resistance arteries in peritoneal dialysis patients. J Am Soc Nephrol 16 6 (2005) 1832-1838
25. Böger R.H. The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor. Cardiovasc Res 59 4 (2003) 824-833
26. Suda O., Tsutsui M., Morishita T., et al. Asymmetric dimethylarginine causes arteriosclerotic lesions in endothelial nitric oxide synthase-deficient Mice. Involvement of renin-angiotensin system and oxidative stress. Arterioscler Thromb Vasc Biol 24 (2004) 1-7
27. Valkonen V, Laakso J, Pisrkanen M, Laaksonen R, Salonen JT, Tuomainen T. Nucleic acid molecule encoding a varaint DDAH1 protein and uses thereof. Patent WO03089638 posted 2003-10-30 available at http://gb.espacenet.com.
28. Schachinger V., Britten M.B., and Zeiher A.M. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 101 16 (2000) 1899-1906
29. Gokce N., Keaney Jr. J.F., Hunter L.M., et al. Predictive value of noninvasively determined endothelial dysfunction for long-term cardiovascular events in patients with peripheral vascular disease. J Am Coll Cardiol 41 10 (2003) 1769-1775
30. Heitzer T., Schlinzig T., Krohn K., Meinertz T., and Münzel T. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 104 22 (2001) 2673-2678 [Erratum in: Circulation. 2003; 108(4):500]
31. Anderson T.J., Uehata A., Gerhard M.D., et al. Close relation of endothelial function in the human coronary and peripheral circulations. J Am Coll Cardiol 26 5 (1995) 1235-1241
32. Teragawa H., Ueda K., Matsuda K., et al. Relationship between endothelial function in the coronary and brachial arteries. Clin Cardiol 28 10 (2005) 460-466
33. Lind L., Fors N., Hall J., Marttala K., and Stenborg A. A comparison of three different methods to evaluate endothelium-dependent vasodilation in the elderly: the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) study. Arterioscler Thromb Vasc Biol 25 11 (2005) 2368-2375
34. Hirooka Y., Egashira K., Imaizumi T., et al. Effect of l-arginine on acetylcholine-induced endothelium-dependent vasodilation differs between the coronary and forearm vasculatures in humans. J Am Coll Cardiol 24 4 (1994) 948-955
35. Furchgott R.F., and Zawadzki J.V. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 288 5789 (1980) 373-376
36. Egashira K., Inou T., Yamada A., Hirooka Y., and Takeshita A. Preserved endothelium-dependent vasodialtion at the vasopsastic site in patients with variant angina. J Clin Invest 89 3 (1992) 1047-1052
37. Lundman P., Eriksson M.J., Stuhlinger M., Cooke J.P., Hamsten A., and Tornvall P. Mild-to-moderate hypertriglyceridemia in young men is associated with endothelial dysfunction and increased plasma concentrations of asymmetric dimethylarginine. J Am Coll Cardiol 38 1 (2001) 111-116
38. Cooke J.P. Asymmetrical dimethylarginine: the Über marker?. Circulation 109 15 (2004) 1813-1818
39. Böger R.H., Sydow K., Borlak J., et al. LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells: involvement of S-adenosylmethionine-dependent methyltransferases. Circ Res 87 2 (2000) 99-105
40. Morange P.E., Simon C., Alessi M.C., et al., PRIME Study Group. Endothelial cell markers and the risk of coronary heart disease: the Prospective Epidemiological Study of Myocardial Infarction (PRIME) study. Circulation 109 11 (2004) 1343-1348
41. Sydow K., and Münzel T. ADMA and oxidative stress. Atherosclerosis 4 Suppl (2003) 41-51
42. Kunsch C., and Medford R.M. Oxidative stress as a regulator of gene expression in the vasculature. Circ Res 85 8 (1999) 753-766
43. Vecchione C., and Brandes R.P. Withdrawal of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors elicits oxidative stress and induces endothelial dysfunction in mice. Circ Res 91 2 (2002) 173-179
44. Laufs U., Wassmann S., Hilgers S., Ribaudo N., Bohm M., and Nickenig G. Rapid effects on vascular function after initiation and withdrawal of atorvastatin in healthy, normocholesterolemic men. Am J Cardiol 88 11 (2001) 1306-1307
45. Maas R. Pharmacotherapies and their influence on asymmetric dimethylargine (ADMA). Vasc Med 10 Suppl 1 (2005) S49-S57
46. John S., Schlaich M., Langenfeld M., et al. Increased bioavailability of nitric oxide after lipid-lowering therapy in hypercholesterolemic patients. Circulation 98 3 (1998) 211-216
47. Maas R., Böger G.I., Schwedhelm E., et al. Effects of simvastatin and l-arginine either alone or in combination on endothelium-dependent vasodialtion in Patients with elevated plasma ADMA levels. Naunyn Schmiedebergs Arch Pharmacol 369 Suppl 1 (2004) R146 [Abstract]
48. Treasure C.B., Klein J.L., Weintraub W.S., et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 332 8 (1995) 481-487
49. Vita J.A., Yeung A.C., Winniford M., et al. Effect of cholesterol-lowering therapy on coronary endothelial vasomotor function in patients with coronary artery disease. Circulation 102 8 (2000) 846-851